Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 in HPV16 Positive Women (URVIVE)
NCT07407569Phase 2Recruiting
- Sponsor
- University of Antwerp
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus type 16 infection (HPV-16), sponsored by University of Antwerp. Started Mar 2026; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus type 16 infection (HPV-16)
Beyond the preview
Go deeper on NCT07407569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407569.